APA (7th ed.) Citation

Kayser, S., Sartor, C., Luskin, M. R., Webster, J., Giglio, F., Panitz, N., . . . Papayannidis, C. (2022). Outcome of relapsed or refractory acute B-lymphoblastic leukemia patients and BCR-ABL-positive blast cell crisis of B-lymphoid lineage with extramedullary disease receiving inotuzumab ozogamicin. Haematologica, 107(9), . https://doi.org/10.3324/haematol.2021.280433

Chicago Style (17th ed.) Citation

Kayser, Sabine, et al. "Outcome of Relapsed or Refractory Acute B-lymphoblastic Leukemia Patients and BCR-ABL-positive Blast Cell Crisis of B-lymphoid Lineage with Extramedullary Disease Receiving Inotuzumab Ozogamicin." Haematologica 107, no. 9 (2022). https://doi.org/10.3324/haematol.2021.280433.

MLA (9th ed.) Citation

Kayser, Sabine, et al. "Outcome of Relapsed or Refractory Acute B-lymphoblastic Leukemia Patients and BCR-ABL-positive Blast Cell Crisis of B-lymphoid Lineage with Extramedullary Disease Receiving Inotuzumab Ozogamicin." Haematologica, vol. 107, no. 9, 2022, https://doi.org/10.3324/haematol.2021.280433.